Targeting MDA-9 restrains head and neck tumor growth and eliminates therapy resistance

Chemotherapy remains a cornerstone of treatment for head and neck cancers, the seventh-most common cancer type worldwide. However, the disease is often diagnosed at a late stage once it has already spread to other organs, and the majority of patients on active treatment will develop resistance to chemotherapy within a matter of months, underscoring a prominent avenue for designing more effective care strategies.